DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma ...Middle East

New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with DARZALEX FASPRO® were progression free at 4.5 years Subgroup analysis from Phase 3 AURIGA study show higher rates of MRD-negative conversion in patient populations...

Hence then, the article about darzalex faspro daratumumab and hyaluronidase fihj based regimens demonstrate improved rates of minimal residual disease mrd negativity and progression free survival in patients with newly diagnosed multiple myeloma was published today ( Monday 09/12/2024 - 03:45 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma )

Also on site :

• Hackers Pose as Microsoft Support to Breach Corporate Defenses .. PYMNTS.com
• Why Shashank Singh is not playing today's match vs RR in IPL 2026?
• Goldie Hawn Opens up About Family—and the Inspiration Behind Her New Children’s Book